CRYSTAL LAKE, Unwell.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a world chief in drug supply, shopper product allotting and lively packaging options, introduced that its Activ-Movie™ know-how was chosen to guard a brand new SARS Speedy Antigen take a look at for COVID-19 that lately acquired Emergency Use Authorization (EUA) from the U.S. Meals and Drug Administration (FDA).
The QuickVue® SARS Antigen take a look at is a point-of-care fast antigen take a look at developed by Quidel® Company, a number one producer of diagnostic healthcare options, that delivers take a look at leads to 10 minutes. The visually learn take a look at requires no supplemental instrumentation and presents expanded entry to inexpensive and correct COVID-19 testing that may assist meet the pressing testing wants of the worldwide economic system, together with for these in class programs and rural areas.
Aptar CSP Applied sciences’ Activ-Movie™ know-how is built-in into the diagnostic equipment to guard in opposition to moisture and different environmental circumstances that might in any other case impression take a look at accuracy. Activ-Movie™ leverages Aptar’s proprietary 3-Part Activ-Polymer™ know-how, which gives a broad spectrum of custom-engineered safety in quite a lot of configurations, corresponding to Activ-Vial™ for housing diagnostics dipsticks and Activ-Tab built-in inside diagnostic cassettes. This materials science-based lively packaging know-how is at present used to guard a variety of electrochemical, lateral circulate and molecular diagnostic take a look at kits available on the market at this time.
“We’re happy to companion with Quidel® Company on this essential diagnostic instrument and assist carry the QuickVue® SARS Antigen take a look at to the market,” stated Stephan B. Tanda, Aptar President and CEO. “Our materials science Activ-Movie™ know-how protects the take a look at strips, serving to to supply fast, dependable outcomes. We’ll proceed to stay as much as our objective and duty to society by offering options that defend essential COVID-19 diagnostic kits, together with allotting options for medicines and shopper merchandise wanted by thousands and thousands of individuals every day.”
Badre Hammond, Vice President Industrial Operations, Aptar CSP Applied sciences concluded, “As we proceed to navigate by the COVID-19 disaster, this game-changing resolution will assist meet the pressing demand for COVID-19 testing in communities around the globe. We’re dedicated to leveraging our materials science experience to allow our companions to fulfill the continuing want for progressive healthcare options that assist enhance and save lives.”
Aptar is a world chief within the design and manufacturing of a broad vary of drug supply, shopper product allotting and lively materials options. Aptar’s progressive options and companies serve quite a lot of finish markets together with pharmaceutical, magnificence, private care, residence, meals and beverage. Utilizing insights, design, engineering and science to create allotting, dosing and protecting packaging applied sciences for lots of the world’s main manufacturers, Aptar in flip makes a significant distinction within the lives, appears, well being and houses of sufferers and customers around the globe. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 devoted workers in 20 nations. For extra data, go to www.aptar.com.
This press launch comprises forward-looking statements. Expressions or future or conditional verbs corresponding to “will” are supposed to establish such forward-looking statements. Ahead-looking statements are made pursuant to the secure harbor provisions of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 and are primarily based on our beliefs in addition to assumptions made by and data at present accessible to us. Accordingly, our precise outcomes might differ materially from these expressed or implied in such forward-looking statements on account of recognized or unknown dangers and uncertainties that exist in our operations and enterprise setting together with, however not restricted to: the profitable integration of acquisitions; the regulatory setting; and competitors, together with technological advances. For added data on these and different dangers and uncertainties, please see our filings with the Securities and Trade Fee, together with the dialogue beneath “Danger Elements” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” in our Kind 10-Ks and Kind 10-Qs. We undertake no obligation to replace any forward-looking statements, whether or not because of new data, future occasions or in any other case.